Kymera Therapeutics, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.kymeratx.com

Moat Score

Market Cap $3.02B
PE -18
Debt $NaN
Cash $110.72M
EV $NaN
FCF -$148.20M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$167.47M
EBIT	-$200.19M
ROE	-19%
ROA	-19%
FCF	-$148.20M
Equity	$892.93M
Growth Stability	1
PE	-18.04
PB	3.38
P/FCF	-20.39
P/S	34.51
Price/Cash	0.04
Net Margins	-386%
Op. Margins	-229%
Sales Growth YoY	-21%
Sales Growth QoQ	-85%
Sales CAGR	19%
FCF CAGR	-0%
Equity CAGR	24%
Earnings Growth YoY	18%

Earnings Growth QoQ	49%
Sales CAGR 5Y	19%
FCF CAGR 5Y	-0%
Equity CAGR 5Y	24%
Earnings CAGR 3Y	15%
Sales CAGR 3Y	15%
Equity CAGR 3Y	21%
Market Cap	$3.02B
Revenue	$87.56M
Assets	$1.03B
Cash	$110.72M
Shares Outstanding	64.75M
Moat Score	2%
Working Capital	502.18M
Current Ratio	8.55
Shares Growth 3y	9%
Equity Growth QoQ	30%
Equity Growth YoY	126%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

SEC Filings

Direct access to Kymera Therapeutics, Inc. (KYMR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Kymera Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Kymera Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Kymera Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Kymera Therapeutics, Inc..

Years

Calculation mode

= -$1.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$148M	-$148M	-$148M	-$148M	-$147M	-$147M	-$147M	-$147M	-$147M	-$146M	-$146M	-$1.5B
DCF		-$135M	-$122M	-$111M	-$101M	-$91M	-$83M	-$75M	-$68M	-$62M	-$56M	-$563M
Value	-$1.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-1K%	-161%	-138%	-331%	-187%	-386%
ROA	-	-10%	-17%	-27%	-29%	-19%
ROE	-	-19%	-22%	-32%	-37%	-19%

Bad Net Margins (-385.87%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	1K%	114%	-36%	68%	19%
Earnings YoY growth	-	32%	83%	54%	-5%	-
Equity YoY growth	-	-482%	62%	7%	-19%	24%
FCF YoY growth	-	355%	-265%	19%	-12%	-0%